Skip Navigation


Cardiovascular Research Advance Access originally published online on June 11, 2008
Cardiovascular Research 2008 79(3):357-359; doi:10.1093/cvr/cvn153
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
79/3/357    most recent
cvn153v2
cvn153v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ward, M. R.
Right arrow Articles by Stewart, D. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ward, M. R.
Right arrow Articles by Stewart, D. J.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Erythropoietin and mesenchymal stromal cells in angiogenesis and myocardial regeneration: one plus one equals three?

Michael R. Ward and Duncan J. Stewart*

Ottawa Health Research Institute, The Ottawa Hospital Civic Campus, 725 Parkdale Ave., Ottawa, ON, Canada K1Y 4E9

* Corresponding author. Tel: +1 613 761 5341; fax: +1 613 761 4920. E-mail address: djstewart@ohri.ca

This editorial refers to ‘Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties’ by I.B. Copland et al.,30 pp. 405–415, this issue.

The first 10% of the full text of this article appears below.

There is an increasing interest in cellular therapy for cardiovascular diseases. The first well-designed clinical trials have shown tantalizing hints that bone marrow cells may improve cardiac function post-myocardial infarction (post-MI)1,2 and enhance perfusion in patients with critical limb ischaemia.3 This cautious optimism comes on the heels of the great disappointment with pro-angiogenic gene therapy, which failed to live up to the promise based on encouraging pre-clinical studies and early, largely anecdotal clinical experience.4 However, even accepting that cell therapy may have a significant beneficial effect, the magnitude of this benefit would seem to be rather modest.5 Although there are many reasons for this, related both to the host (age, cardiovascular risk factors, and co-morbidities) as well as the cells themselves (type, ‘dose’, delivery route, and activity), it seems clear that strategies to enhance the regenerative capacity of stem or . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article

Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties
Ian B. Copland, E. Marc Jolicoeur, Marc-Antoine Gillis, Jessica Cuerquis, Nicoletta Eliopoulos, Borhane Annabi, Angelo Calderone, Jean-Francois Tanguay, Anique Ducharme, and Jacques Galipeau
Cardiovasc Res 2008 79: 405-415. [Abstract] [Full Text] [PDF]